Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can blocking rogue immune cells stop a leading cause of blindness?

NCT ID NCT04697095

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study tests whether immune cells called monocytes from people with the atrophic form of age-related macular degeneration (AMD) survive longer on retinal cells than monocytes from healthy people. Researchers will collect blood samples from 80 participants, extract monocytes, and culture them on retinal pigment epithelial cells in the lab. The goal is to understand why these cells accumulate in the retina and whether targeting them could lead to future treatments for atrophic AMD, which currently has no therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood sample collection for monocyte extraction and laboratory analysis
What this could lead to
If monocytes from atrophic AMD patients survive longer on retinal cells, it could point to new therapies that block this harmful accumulation.
What could go wrong
This is an early laboratory study with a small sample, so findings may not translate to treatments. The research only observes cells, not living patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: General criteria: * Male or female older than 50, * Provide written informed consent, * Patient affiliated to French social security, * Maximum sampling volume (care + research) per 30-day period to be adapted according to the weight of the patient Specific criteria: Patient presenting in both eyes: * Either the same type of AMD defined according to the modified international AREDS study (Ferris et al. 2013), * or early AMD in one eye and atrophic AMD in the other eye, the patient will therefore be defined as being atrophic * or early AMD in one eye and exudative AMD in the other eye, the patient will therefore be defined as exudative, * or no retinal pathology (control group). Exclusion Criteria: General criteria: * Patient whose weight is less than 50kg, * Adult patient under guardianship or curatorship or unable to express consent, * Person deprived of liberty, * Patient participating in an ongoing clinical trial during the inclusion visit, Specific criteria: * Patient with atrophic AMD in one eye and exudative AMD in the other eye, * Patient presenting with chronic retinal pathologies other than AMD, defined according to the modified international AREDS study (Ferris et al. 2013) , in the included eye, * Patient taking systemic drugs with an immunomodulatory action: immunosuppressants, immunomodulators, chemotherapy or corticosteroids, * Patient with systemic pathologies modifying their immune status, * Patient with a history of diabetes, * Patient who had dynamic phototherapy on the included eye.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age related macular degeneration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Inflammation macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age related macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Edouard Herriot

    RECRUITING

    Lyon, 69003, France

  • Service d'ophtalmologie-HOSPICES CIVILS DE LYON - Hôpital de la Croix-Rousse

    RECRUITING

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.